BIRC5 showed affinity for anti-mitotic agents such as berberine, aligning with its function in cellular survival (58), whereas THY1 and FN1 were anticipated to engage with immune checkpoint inhibitors, reinforcing their promise in combinatorial therapy designed to augment anti-tumour immunity. The gene discussed is THY1; the disease is neoplasm.